Schwab Network on $JNJ

Channel profile →Sources cited by the channel: BFA and JP Morgan, Baird, Bank of America, Barclays, Berenberg, Bernstein, with a Jefferies target cut noted, Bird (analyst firm), CEO, CEO Joe Dominguez, Caner, Citi, Citigroup, Citizens, Daiwa, Dan Deming and Michael Monahan, Dan Ives, Deutsche Bank, Erit Research, Evercore ISI, Evercore ISI; Dan Ives, Goldman Sachs, JP Morgan Chase, JPMorgan, JPMorgan Chase, Jefferies, Jefferies, UBS and Citigroup, Jensen Huang; Dan Ives, Loop Capital, Mattie Natsson, Michael Saylor, Milius (analyst), Morgan Stanley, Northrop, Oppenheimer, Oppenheimer, Freedom Broker, Oracle, Reddit CEO, Rothschild Redburn, SK Hynix, Seth, Tim Bigham, Tim and KG, Truist, UBS, Wall Street Journal, Wedbush, Wells Fargo, analysts2 entries

Schwab Network has discussed $JNJ in 2 videos since 2026-10-13. The latest, on 2026-10-29, was bullish.

2026-10-29Bullish

“The Big 3: AAPL, JNJ, MMM”

AI summary · JNJ is a buying opportunity and a long-term core holding: post-earnings momentum and healthcare's defensive strength support further upside, with the weekly trend up since June 2025; a break above 275 and then the 278 high opens the 290 resistance, the only caution being a weekly RSI bearish divergence.

Our second choice is Johnson & Johnson. Their profits have exceeded expectations despite incurring significant losses during the quarter, and they are still rising. They rose in today's session .

They have been rising since announcing their earnings. Not a huge increase, but they are positive. How do you view Johnson & Johnson now, Dan?

Read transcript and source

2026-10-13

“Tuesday's First Moves: WFC Mixed Earnings, JNJ Beat & Raise, DPZ Slides”

AI summary · JNJ beat on profit and revenue yet shares fell about 4%: pharma grew on Tremfya while Stelara declined, and medical technology rose only 2.5% to $8.6B, below expectations — blamed on the Middle East conflict, European austerity and China price pressure, the source of the stock's weakness.

Let's talk about Johnson & Johnson. At Johnson & Johnson, the picture is weaker , with shares under pressure and down about 4% despite the company beating expectations in net profit.

Earnings amounted to $2.59 per share . Analysts had expected $2.53 per share. Revenues also recorded a slight increase, reaching $25.4 billion. The market had been expecting $25.25 billion for Johnson & Johnson, but they noted there would be some impact on the medical technology sector .

That was the weakest point, and some of that is due to the geopolitical conflict they mentioned. Sales outside the United States were essentially stable . Once again, total revenues reached $25.4 billion, while the expected amount was $25.25 billion.

Read transcript and source